Versant Ventures has launched Matterhorn Biosciences AG, a biotech company focused on developing T cell receptor therapies. Versant has committed $30 million to Matterhorn.
Source: Press Release
Versant Ventures commits $30m to Matterhorn Biosciences
Versant Ventures has launched Matterhorn Biosciences AG, a biotech company focused on developing T cell receptor therapies.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: